We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

QIAGEN

Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including comple... read more Featured Products: More products

Download Mobile App




Qiagen and Eli Lilly to Develop First QIAstat-Dx IVD Panel for Neurodegenerative Applications

By LabMedica International staff writers
Posted on 06 Sep 2024
Print article
Image: The QIAstat-Dx IVD panel for neurodegenerative applications will be integrated with the QIAstat-Dx multiplex testing platform (Photo courtesy of QIAGEN)
Image: The QIAstat-Dx IVD panel for neurodegenerative applications will be integrated with the QIAstat-Dx multiplex testing platform (Photo courtesy of QIAGEN)

QIAGEN N.V. (Venlo, the Netherlands) has entered into a collaboration with Eli Lilly and Company (Indianapolis, IN, USA) to support the development of a QIAstat-Dx in-vitro diagnostic (IVD) to detect APOE genotypes. The QIAstat-Dx panel would be the first commercially available IVD for APOE genotyping and will detect all APOE genotypes (APOE2, APOE3, APOE4) which can play a role in the diagnosis of Alzheimer’s disease. People carrying the APOE4 genotype have a greater risk of developing Alzheimer's which is the most common cause of dementia and are likely to do so earlier in life in comparison to others. Individuals carrying two copies of this genotype (homozygous) are most likely to develop clinical symptoms of the disease.

The panel will be integrated with QIAGEN's multiplex testing platform QIAstat-Dx, marking the first publicly disclosed collaboration for the system’s clinical application in neurodegenerative diseases. The QIAstat‑Dx system, designed for laboratory use, utilizes cost-efficient, single-use cartridges with built‑in sample processing and on-board reagents. Employing multiplex real-time PCR, it reliably detects genetic variants, with results in approximately one hour. With over 4,000 instruments placed worldwide, QIAstat‑Dx enjoys a strong footprint in infectious disease testing, which has now expanded into other disease and application areas.

“Our collaboration with Lilly to develop the QIAstat-Dx IVD panel underlines our commitment to advancing healthcare with a unique breadth of testing technologies and platforms, now also including multiplexing capabilities on QIAstat‑Dx,” said Jonathan Arnold, Vice President and Head of Translational Science and Precision Diagnostics at QIAGEN. “By providing precise APOE genotyping, we aim to better inform treatment considerations for Alzheimer’s patients, providing valuable insight in their diagnostic journey.”

“When offering a diagnostic test for clinical use, it is imperative that it be high-quality, accurate and accessible to patients,” added Anthony Sireci, M.D., MSc., Head of Diagnostics Development & Commercialization for Eli Lilly and Company. “We are working with QIAGEN to generate data for this APOE test because of their expertise in developing diagnostic assays and their global reach.”

Related Links:
QIAGEN N.V.
Eli Lilly and Company

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Electroporation System
Gibco CTS Xenon
New
STI Test
cobas TV/MG

Print article

Channels

Molecular Diagnostics

view channel
Image: The kit includes a container with a film, a compact optical device for attaching a smartphone, and a diagnostic app (Photo courtesy of KIST)

Urine-Based Bladder Cancer Diagnostic Kit to Reduce Need for Unnecessary Cystoscopies

Bladder cancer has a high cure rate of over 90% when detected early, but it is characterized by a recurrence rate of 70%, which requires continuous monitoring. Late-stage detection often results in major... Read more

Microbiology

view channel
Image: The QIAstat-Dx mini gastrointestinal panel has secured U.S. clearance to support year-round outpatient care (Photo courtesy of QIAGEN)

Syndromic Panel Provides Fast Answers for Outpatient Diagnosis of Gastrointestinal Conditions

Acute infectious gastroenteritis is a major cause of outpatient visits and hospitalizations in the U.S., with over 179 million cases estimated annually. Now, a new gastrointestinal panel designed to provide... Read more

Pathology

view channel
Image: The AI tool can search through data and histology images for much more precise information on cancer treatment effectiveness (Photo courtesy of Shutterstock)

AI Tool Analyzes 30K Data Points Per Medical Imaging Pixel in Cancer Search

A new artificial intelligence (AI)-powered tool can detect cell-level characteristics of cancer by analyzing data from very small tissue samples, some as tiny as 400 square micrometers, equivalent to the... Read more

Technology

view channel
Image: Human tear film protein sampling methods (Photo courtesy of Clinical Proteomics. 2024 Mar 13;21:23. doi: 10.1186/s12014-024-09475-8)

New Lens Method Analyzes Tears for Early Disease Detection

Bodily fluids, including tears and saliva, carry proteins that are released from different parts of the body. The presence of specific proteins in these biofluids can be a sign of health issues.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.